Business Context and Reporting Period
This Form 8-K Current Report was filed by NextCure, Inc. on July 31, 2020, covering events occurring on July 27, 2020. The filing discloses the execution of new employment agreements with three key executives: Michael Richman (President and CEO), Steven P. Cobourn (CFO), and Solomon Langermann, Ph.D. (CSO). These agreements supersede prior contracts.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation terms.
- CEO Base Salary: $500,000 annually.
- CFO Base Salary: $325,000 annually.
- CSO Base Salary: $375,000 annually.
- Target Cash Bonus: 50% of base salary for the CEO; 35% of base salary for the CFO and CSO.
Material Changes Versus Prior Period
The primary material change is the replacement of prior employment agreements with new contracts effective July 27, 2020. The new agreements formalize specific base salaries and bonus targets, whereas the filing does not detail the specific terms of the superseded agreements for direct numerical comparison.
Guidance, Outlook, and Risks
Severance and Change in Control Provisions:
- Standard Termination: If terminated without Cause or for Good Reason, the CEO receives 12 months of base salary, while the CFO and CSO receive 9 months. Health insurance coverage continues at the Company's expense for the same duration.
- Change in Control: If termination occurs within three months prior to or 12 months following a Change in Control, severance extends to 18 months for the CEO and 12 months for the CFO and CSO.
Management Commentary: The filing states that bonuses are determined by the Board of Directors based on pre-determined performance milestones. No specific operational guidance or financial outlook is provided in this report.
Investor Verification Checklist
- Verify the full text of Exhibits 10.1, 10.2, and 10.3 for detailed definitions of "Cause," "Good Reason," and "Change in Control."
- Confirm the specific performance milestones required to achieve the target cash bonuses.
- Review the Company's most recent 10-Q or 10-K to assess the impact of these compensation increases on operating expenses and cash burn rate.
- Check for any concurrent filings regarding equity grants or stock option awards not detailed in this summary.